Skip to main content
OpenTrials
Completed

NCT Number: NCT04172012

Use of Probiotics to Reduce Infections, Death and ESBL Colonisation

This study examines the effect of oral probiotic treatment to newborns on preventing hospitalizations, death and colonization with Extended-spectrum beta-lactamase-producing Gram negative bacteria. Half of the babies will receive 4 weeks treatment with an oral mixture of the probiotic Labinic (R) while the other half will receive a placebo mixture.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 3 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Haydom Lutheran Hospital

Babati, Manyara Region, Tanzania

About this study

Studies show that probiotics given to prematurely born babies prevents sepsis and is widely used in the western world for this purpose. Probiotics consists of one or more normal gut-bacteria. A large study in India showed that giving probiotics to full-born babies reduced hospitalizations and morbidity. This study investigates giving a probiotic mixture with different combination of bacteria, Lactobacillus acidophilus, Bifidobacterium infantis and Bifidobacterium breve, for a longer duration (4 weeks instead of 7 days).

Infections with antibiotic-resistant bacteria is a major threat to health-care world-wide, and sepsis/severe infection caused by such bacteria is a major cause of neonatal death. The study hypothesis is that giving probiotics to newborns prevents them from getting colonized with antibiotic-resistant bacteria, such as Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). By preventing colonization with ESBL-PE, severe infections such as sepsis may be prevented, and thereby survival may be improved.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy newborn infants with a birth weight equal or above 2.0 kgs, will be included in the study between 0-3 days of life.
  • Newborn infants have to come from families who are long-term or permanent residents in the defined catchment area for this trial (30 km radius from HLH) in Tanzania.
  • Parents are able and willing to complete study visit (including required study procedures) schedules over the six months proposed follow-up, which also includes hospitalizations required for compliance of this study protocol.
  • Parents agrees for the child not to participate in another study during the study period
  • Children less than one year admitted to hospital with suspected infection, not included in the RCT, will be included in a sub-study. A separate inclusion form is prepared for these children.

Exclusion criteria

  • Birth weight below 2 kg
  • Other health problems/illness, obvious congenital malformations.
  • Multiple pregnancy
  • Parents not consenting

Treatment and study plan

Labinic (R) probiotic mixture

Biological

Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve

Placebo

Other

Placebo mixture

Primary outcomes

  1. Composite outcome hospitalization and death

    Time frame: 6 months from inclusion

    Primary outcome is hospitalization and/or death of study subject

Secondary outcomes

  1. ESBL colonization

    Time frame: 6 weeks and 6 months

    Faecal colonisation with Extended-spectrum beta-lactamase-producing Enterobacteriaceae as detected by fecal swab

  2. Hospitalisation

    Time frame: 6 weeks and 6 months

    Hospitalisation

  3. Death

    Time frame: 6 months

    Death during study period

  4. Body weight

    Time frame: 6 months

    Growth monitored by weight

  5. Body length

    Time frame: 6 months

    Growth monitored by length

  6. Stool microbiota

    Time frame: 6 weeks and 6 months

    Stool microbiota composition including resistome analysis (metagenome sequencing)

  7. Stool metabolome

    Time frame: 6 weeks and 6 months

    Stool metabolome composition

  8. Stool inflammatory markers - Calprotectin

    Time frame: 6 weeks and 6 months

    Levels of Calprotectin in participants' stool samples

  9. Stool inflammatory markers - alpha-1 antitrypsin

    Time frame: 6 weeks and 6 months

    Levels of alpha-1 antitrypsin (AAT) in participants' stool samples

  10. Stool inflammatory markers - myeloperoxidase

    Time frame: 6 weeks and 6 months

    Levels of human myeloperoxidase (MPO) in participants' stool samples

  11. Number of participants with culture-confirmed bacteremia

    Time frame: 6 months

    Bacteremia confirmed by blood culture

  12. Genetic characteristics of ESBL-producing Enterobacteriaceae

    Time frame: 6 weeks and 6 months

    Genetic characteristics of ESBL-E from colonization and clinical samples (targeted screening)

Sponsors and collaborators

Lead sponsor

Haydom Lutheran Hospital

Other

Collaborators

  • Helse Stavanger HF
  • Muhimbili University of Health and Allied Sciences
  • UiT The Arctic University of Norway
  • University of Bergen

Registry information

Official study title

Use of Probiotics to Reduce Infections and Death and Prevent Colonization With Extended-spectrum Beta-lactamase Producing Bacteria, Among Newborn Infants in Haydom and Surrounding Area, Tanzania, a Randomized Controlled Clinical Trial

Acronym: ProRIDE

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Nov 21, 2019
Registry last updated
Apr 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.